Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00634881
Recruitment Status : Completed
First Posted : March 13, 2008
Last Update Posted : May 10, 2018
Information provided by (Responsible Party):
German CLL Study Group